Management of Lymphoma with Steroids, Anakinra, and Intra-entrical Chemotherapy

The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and CAR-T cells demonstrating promising results. At the 2023 EHA meeting, leading experts from around the globe came together to discuss the latest updates in all areas of hematological oncology.

In this podcast, you will hear from Gloria Iacoboni, MD, Vall d’Hebron University Hospital, Barcelona, Spain, and Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, who share some insights into recent advances in CAR-T therapy and bispecific antibodies in the treatment of LBCL. Topics covered include the sequencing of these agents, bridging therapies, and managing toxicities and cytopenias after CAR-T therapy.

The post Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management appeared first on VJHemOnc.